EL7.AI
StocksMedium•16 November 2026•
4 min read

YARTEMLEA revenue jumps 29.6%; Omeros shares fall 10.4% after hours

Key Facts

1YARTEMLEA's total revenue was $41.8 million in the third quarter, up 29.6% from the second quarter.
2Omeros posted a GAAP net loss of $57.4 million, or $0.79 per share, in the third quarter.
3Omeros shares fell 10.4% in after-hours trading on November 16, 2026.
4YARTEMLEA net revenue was about $35.9 million in the third quarter, up 26% from the second quarter.

Omeros reported results for the third quarter ended September 30 on November 16, 2026, and Investing.com said its shares fell 10.4% in after-hours trading following the announcement. The decline came after the company posted a U.S. GAAP net loss of $57.4 million, despite growth in revenue from its YARTEMLEA product and improved operating results. Omeros said the loss was largely tied to a non-cash item from the revaluation of a financial derivative. By contrast, adjusted earnings per share and total YARTEMLEA revenue exceeded analysts' estimates, according to Investing.com. The results were released after the market closed on November 16, while the closing price of $17.49 was from the November 13 session before the announcement.

YARTEMLEA's total revenue was about $41.8 million in the third quarter, up $9.5 million, or 29.6%, from $32.2 million in the second quarter. Net revenue rose 26% to $35.9 million from $28.5 million in the previous quarter. Chief Executive Gregory Demopulos said product sales continued to grow in the third quarter and revenue continued to grow in the fourth quarter. He added that the company is investing in field awareness and working to expand patient access through international regulatory approvals and named-patient programs. The figures reflect sequential growth between the two quarters, while the company's net take from total revenue remains affected by commercial and reimbursement adjustments.

The GAAP net loss was about $57.4 million, or $0.79 per share, compared with net income of $13.2 million, or $0.18 per share, in the second quarter. The company attributed a large part of the loss to a non-cash item of $62.0 million, mainly related to mark-to-market adjustments on a derivative tied to convertible notes due in 2029. Excluding non-cash items, the company posted adjusted non-GAAP net income of $4.7 million, or $0.06 per share. That measure was $1.8 million, or $0.02 per share, in the second quarter. The gap between the accounting loss and adjusted profit highlights the effect of the derivative revaluation on the reported period's results.

On operations, operating income was $4.5 million in the third quarter, compared with $0.1 million in the second quarter. Research and development, selling and administrative expenses combined rose to $30.6 million from $27.7 million in the previous period. The company generated positive operating cash flow of $13.3 million in the third quarter. It also ended September 30 with $95.3 million in cash and short-term investments. These indicators place improved operating income and cash flow alongside higher expenses, as Omeros recorded an accounting net loss.

The gross-to-net revenue adjustment rose to 14.0% in the third quarter, from 11.5% in the second quarter. The company attributed the increase to purchases by entities covered by the 340B program and said it was consistent with an expanding customer base and increased use of the product in outpatient settings. It noted that YARTEMLEA's NTAP status took effect on October 1, allowing eligible hospitals up to $287,079 in additional reimbursement per qualifying inpatient case. The company also said appropriate Medicare outpatient reimbursement for covered 340B purchases of the product begins on January 1, 2027. The company links these arrangements to its efforts to expand patient access, while the higher revenue adjustment points to the effect of covered program purchases on the gap between gross and net revenue.

Narsoplimab faced a European regulatory setback, as Omeros said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion in October on the marketing application for the drug to treat TA-TMA. The opinion followed a re-examination of an initial negative opinion issued in June 2026. For its other development programs, the company expects to begin enrolling participants in an OMS527 trial for cocaine use disorder in the first quarter of 2027. It said this follows a nonclinical study in response to a request for additional information from the U.S. Food and Drug Administration. It also targets starting a Phase 1b human trial for the OncotoX-AML program and evaluating OMS805 in late 2027.

Management's call to discuss the results and provide a business update was scheduled for November 16 at 4:30 p.m. Eastern time, and the company said a replay would remain available online for 90 days. In the November 13 session, before the results announcement, OMER shares closed at $17.49. The 10.4% decline reported by Investing.com came in after-hours trading on November 16, following the release of the results. The platform linked the fall to the large accounting loss despite some operating metrics exceeding estimates. The stock's reaction in the announcement session therefore came at a different time from the closing price recorded three days earlier.

Open on chart